S&P 500   3,382.68 (+0.07%)
DOW   27,931.15 (-0.16%)
QQQ   273.31 (+0.53%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,382.68 (+0.07%)
DOW   27,931.15 (-0.16%)
QQQ   273.31 (+0.53%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,382.68 (+0.07%)
DOW   27,931.15 (-0.16%)
QQQ   273.31 (+0.53%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
S&P 500   3,382.68 (+0.07%)
DOW   27,931.15 (-0.16%)
QQQ   273.31 (+0.53%)
AAPL   457.16 (+1.13%)
MSFT   209.25 (+0.03%)
FB   260.76 (+0.33%)
GOOGL   1,524.26 (+1.13%)
AMZN   3,205.09 (+1.36%)
NVDA   463.50 (+1.29%)
CGC   17.44 (+1.10%)
BABA   253.39 (-0.71%)
TSLA   1,607.64 (+3.40%)
GE   6.67 (-0.74%)
MU   46.66 (-3.75%)
AMD   82.47 (-0.17%)
T   30.02 (-0.53%)
F   7.14 (+0.42%)
ACB   9.69 (-1.12%)
GILD   68.33 (-0.74%)
NFLX   477.14 (+0.35%)
DIS   131.85 (+0.05%)
BAC   26.37 (-1.35%)
BA   177.79 (+1.34%)
Log in

NASDAQ:GWPHGW Pharmaceuticals PLC- Stock Price, Forecast & News

$108.99
-0.01 (-0.01 %)
(As of 08/13/2020 10:26 AM ET)
Add
Compare
Today's Range
$108.99
Now: $108.99
$108.99
50-Day Range
$109.37
MA: $127.91
$139.54
52-Week Range
$67.98
Now: $108.99
$162.13
Volume4 shs
Average Volume474,237 shs
Market Capitalization$3.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.92
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More
GW Pharmaceuticals PLC- logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GWPH
CUSIPN/A
Phone44-12-2326-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$311.33 million
Book Value$23.48 per share

Profitability

Net Income$-9,020,000.00

Miscellaneous

Employees791
Market Cap$3.38 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$108.99
-0.01 (-0.01 %)
(As of 08/13/2020 10:26 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GWPH News and Ratings via Email

Sign-up to receive the latest news and ratings for GWPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GW Pharmaceuticals PLC- (NASDAQ:GWPH) Frequently Asked Questions

How has GW Pharmaceuticals PLC-'s stock price been impacted by Coronavirus (COVID-19)?

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GWPH stock has increased by 25.4% and is now trading at $108.99.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GW Pharmaceuticals PLC-?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GW Pharmaceuticals PLC-
.

When is GW Pharmaceuticals PLC-'s next earnings date?

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for GW Pharmaceuticals PLC-
.

How were GW Pharmaceuticals PLC-'s earnings last quarter?

GW Pharmaceuticals PLC- (NASDAQ:GWPH) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The biopharmaceutical company had revenue of $121.30 million for the quarter, compared to analysts' expectations of $94.57 million. GW Pharmaceuticals PLC- had a negative net margin of 12.56% and a negative return on equity of 7.71%. The firm's revenue was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.21 earnings per share.
View GW Pharmaceuticals PLC-'s earnings history
.

What price target have analysts set for GWPH?

12 analysts have issued twelve-month target prices for GW Pharmaceuticals PLC-'s shares. Their forecasts range from $128.00 to $275.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $185.08 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price.
View analysts' price targets for GW Pharmaceuticals PLC-
.

Has GW Pharmaceuticals PLC- been receiving favorable news coverage?

Media stories about GWPH stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
View the latest news about GW Pharmaceuticals PLC-
.

Who are some of GW Pharmaceuticals PLC-'s key competitors?

What other stocks do shareholders of GW Pharmaceuticals PLC- own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Netflix (NFLX), Aurora Cannabis (ACB), Intel (INTC), Gilead Sciences (GILD) and Cronos Group (CRON).

Who are GW Pharmaceuticals PLC-'s key executives?

GW Pharmaceuticals PLC-'s management team includes the following people:
  • Dr. Geoffrey W. Guy BSc, LMSSA, Dip Pharm Med, MB BS, MRCS Eng, LRCP, Founder & Chairman (Age 65)
  • Mr. Justin D. Gover, CEO & Exec. Director (Age 48)
  • Mr. Scott M. Giacobello, Chief Financial Officer (Age 49)
  • Mr. Douglas B. Snyder, Chief Legal Officer (Age 55)
  • Mr. Julian S. Gangolli, U.S. Chief Commercial Officer (Age 61)

What is GW Pharmaceuticals PLC-'s stock symbol?

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

Who are GW Pharmaceuticals PLC-'s major shareholders?

GW Pharmaceuticals PLC-'s stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.85%), M&G Investment Management Ltd. (1.72%), Bank of New York Mellon Corp (1.20%), Redwood Investments LLC (0.42%), Candriam Luxembourg S.C.A. (0.39%) and Roosevelt Investment Group Inc. (0.30%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals PLC-
.

Which institutional investors are selling GW Pharmaceuticals PLC- stock?

GWPH stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Victory Capital Management Inc., Tekla Capital Management LLC, Roosevelt Investment Group Inc., D.A. Davidson & CO., Advisors Asset Management Inc., GW&K Investment Management LLC, and Janney Montgomery Scott LLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals PLC-
.

Which institutional investors are buying GW Pharmaceuticals PLC- stock?

GWPH stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Bank of Montreal Can, Candriam Luxembourg S.C.A., RMB Capital Management LLC, Financial Counselors Inc., Trexquant Investment LP, Hardman Johnston Global Advisors LLC, and Quantitative Systematic Strategies LLC.
View insider buying and selling activity for GW Pharmaceuticals PLC-
.

How do I buy shares of GW Pharmaceuticals PLC-?

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GW Pharmaceuticals PLC-'s stock price today?

One share of GWPH stock can currently be purchased for approximately $108.99.

How big of a company is GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC- has a market capitalization of $3.38 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.

What is GW Pharmaceuticals PLC-'s official website?

The official website for GW Pharmaceuticals PLC- is www.gwpharm.com.

How can I contact GW Pharmaceuticals PLC-?

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.